Aljazira Capital, which has initiated coverage on Al Hammadi Development & Investment Co., recommended an “overweight” rating on the stock and set its target price at SAR 56.30.
The decision was based on the company’s expansion plans and a shortage of health care services and facilities in Saudi Arabia, the brokerage firm said in a report.
In addition, Al Hammadi is set to boost its capacity by 340 percent with two new facilities following the opening of Al-Nozha Hospital early next year.
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}